ReviewJournal of cellular and molecular medicine2025
PTBP1 and Cancer: From RNA Regulation to Therapeutic Potential.
Review in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Review
- Metabolic remodeling by circular RNAs in gastric tumorigenesis: From mechanisms to biomarker discovery (Review).International journal of oncology · 2026Review
- Regulation of Tau Alternative Splicing: A Novel Role for the Ribonucleoprotein RBM20.International journal of molecular sciences · 2026Article
- PTBP1 inhibition reprograms myogenesis to rescue impaired muscle regeneration in mdx mice through correcting E2A splicing.Nature communications · 2026Article
- Oncogenic functions of polypyrimidine tract-binding protein 1 in breast cancer metabolism and progression.Biochemistry and biophysics reports · 2026Article
- RSPO2-induced ferroptosis via PTBP1-mediated FSP1 mRNA decay suppresses breast cancer progression.Frontiers in oncology · 2026Article
- PTBP1 and Cancer: From RNA Regulation to Therapeutic Potential.Journal of cellular and molecular medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Polypyrimidine tract binding protein 1 (PTBP1) belongs to the heterogeneous nuclear ribonucleoprotein (hnRNP) family and is a widely studied RNA-binding protein involved in regulating mRNA splicing, stability, localization, and translation. In addition, PTBP1 can participate in various non-coding RNA action processes and affect tumorigenesis and progression. In tumour therapy, PTBP1 may act as a key factor influencing targeted drug targets. Therefore, in this paper, we reviewed the structure and function of PTBP1, its role in various tumours, and key mechanisms of action. Moreover, we discuss the difficulties and challenges faced in PTBP1 research and the clinical translational potential of PTBP1 research and summarise the future research direction of PTBP1 to provide new ideas for basic research and new directions for precision treatment of tumours in the clinic.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.